Wedbush Analysts Reiterate a "Outperform" Rating on Cubist Pharmaceuticals, Inc. (CBST)
Thursday, July 14, 2021 6:11 PM

Equities research analysts at Wedbush reiterated an "outperform" rating on shares of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) in a research note to investors on Thursday.

Separately, analysts at Jefferies raised their price target on shares of Cubist Pharmaceuticals, Inc. to $44.00 in a research note to investors on Thursday, June 2nd. Also, analysts at Global Hunter Securities initiated coverage on shares of Cubist Pharmaceuticals, Inc. in a research note to investors on Friday, May 27th. They set a "neutral" rating on the stock.

Shares of Cubist Pharmaceuticals, Inc. traded down 1.13% during mid-day trading on Friday, hitting $35.93. Cubist Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $39.29. The stock's 50-day moving average is $36.13 and its 200-day moving average is $28.77. The company has a market cap of $2.154 billion and a price-to-earnings ratio of 23.52.

Cubist Pharmaceuticals, Inc. last announced its quarterly results on Thursday, July 14th. The company reported ($0.34) earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of $0.43 EPS by $0.77. The company’s quarterly revenue was up 4.9% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals, Inc. will post $-0.27 EPS next quarter.

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The Company’s products are used primarily in hospitals, but also may be used in acute care settings, including home infusion and hospital outpatient clinics. Cubist’s owns CUBICIN (daptomycin for injection), which is a once-daily, bactericidal, intravenous (I.V.) antibiotic with activity against certain Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (S. aureus), (MRSA). During the year ended December 31, 2009, this product was used in the treatment of more than an estimated 880,000 patients. In December 2009, the Company acquired Calixa Therapeutics Inc.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.